Dapasmart: Advanced Antispasmodic Relief for Gastrointestinal Comfort
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 14 | $5.09 | $71.28 (0%) | 🛒 Add to cart |
| 28 | $4.27 | $142.57 $119.48 (16%) | 🛒 Add to cart |
| 56 | $3.91 | $285.14 $218.87 (23%) | 🛒 Add to cart |
| 84 | $3.75 | $427.71 $315.26 (26%) | 🛒 Add to cart |
| 112 | $3.53 | $570.27 $395.58 (31%) | 🛒 Add to cart |
| 168 | $3.44
Best per pill | $855.41 $577.30 (33%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 14 | $4.80 | $67.27 (0%) | 🛒 Add to cart |
| 28 | $3.91 | $134.54 $109.44 (19%) | 🛒 Add to cart |
| 56 | $3.59 | $269.07 $200.80 (25%) | 🛒 Add to cart |
| 84 | $3.51 | $403.61 $295.18 (27%) | 🛒 Add to cart |
| 112 | $3.41 | $538.15 $381.52 (29%) | 🛒 Add to cart |
| 168 | $3.24
Best per pill | $807.22 $544.17 (33%) | 🛒 Add to cart |
Synonyms | |||
Dapasmart represents a significant advancement in the management of functional gastrointestinal disorders, specifically designed for patients experiencing spasmodic pain and discomfort. This prescription medication contains a targeted antispasmodic agent that works directly on smooth muscle tissue within the gastrointestinal tract, providing rapid and effective relief from cramping and irregular motility. Developed through rigorous clinical research, Dapasmart offers a sophisticated therapeutic option for healthcare providers seeking to restore quality of life for those affected by chronic digestive discomfort. Its optimized formulation ensures both efficacy and a favorable tolerability profile when used under proper medical supervision.
Features
- Active ingredient: Dicyclomine Hydrochloride 10mg
- Pharmaceutical form: Enteric-coated tablet
- Mechanism: Muscarinic receptor antagonist with direct smooth muscle relaxant properties
- Bioavailability: Approximately 70% following oral administration
- Half-life: 9-10 hours in healthy adults
- Metabolism: Hepatic, primarily via CYP3A4 and CYP2D6 isoenzymes
- Excretion: Renal (80%) and fecal (20%)
- Packaging: Blister packs of 30 tablets
Benefits
- Provides rapid relief from abdominal cramping and pain associated with irritable bowel syndrome
- Reduces frequency and severity of spasmodic episodes, allowing for normalized daily activities
- Minimizes disruptive gastrointestinal motility without causing complete cessation of bowel function
- Demonstrates selective action on gastrointestinal smooth muscle with limited systemic effects
- Offers predictable pharmacokinetics with consistent dose-response relationship
- Supports long-term management of chronic functional bowel disorders when used as prescribed
Common use
Dapasmart is primarily indicated for the management of irritable bowel syndrome (IBS) and other functional gastrointestinal disorders characterized by smooth muscle spasm. It is commonly prescribed for patients experiencing recurrent abdominal pain, cramping, bloating, and altered bowel habits where antispasmodic intervention is clinically appropriate. The medication finds particular utility in cases where dietary modifications and lifestyle changes have provided insufficient symptom control. Healthcare providers may also consider Dapasmart for off-label use in certain cases of diverticulitis-related discomfort or as adjunctive therapy in comprehensive pain management protocols for chronic abdominal conditions. Clinical evidence supports its use in both acute symptomatic episodes and maintenance therapy for chronic conditions.
Dosage and direction
The recommended adult dosage of Dapasmart is one 10mg tablet taken four times daily, approximately 30 minutes before meals and at bedtime. Initiate therapy with a lower frequency (twice daily) for the first 3-5 days to assess tolerance, particularly in elderly patients or those with heightened sensitivity to anticholinergic effects. Tablets should be swallowed whole with a full glass of water and should not be crushed or chewed, as this compromises the enteric coating. Administration timing should be consistent from day to day to maintain stable plasma concentrations. For optimal therapeutic effect, patients should take Dapasmart on an empty stomach, at least 1 hour before or 2 hours after meals. Treatment duration should be determined based on symptomatic response and tolerability, with regular reassessment of continuing need every 3-6 months.
Precautions
Exercise caution when prescribing Dapasmart to patients with known or suspected glaucoma, as anticholinergic agents may increase intraocular pressure. Patients with prostatic hypertrophy or bladder outlet obstruction require careful monitoring due to potential urinary retention. Those with cardiovascular conditions, particularly tachycardia or arrhythmias, should be assessed for suitability before initiation. Hepatic impairment necessitates dosage adjustment and close monitoring, as reduced metabolism may lead to accumulation. Renal impairment (creatinine clearance below 30 mL/min) requires a 50% dosage reduction and extended dosing intervals. Elderly patients demonstrate increased sensitivity to anticholinergic effects and typically require lower dosages. Dapasmart may impair mental alertness and physical coordination; patients should avoid operating machinery or driving until their response is established.
Contraindications
Dapasmart is contraindicated in patients with known hypersensitivity to dicyclomine hydrochloride or any component of the formulation. Absolute contraindications include obstructive uropathy, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis, and unstable cardiovascular status in acute hemorrhage. The medication must not be used in patients with narrow-angle glaucoma, even if controlled medically. Gastrointestinal obstruction of any type represents an absolute contraindication due to the risk of complete ileus. Concurrent use with other strong anticholinergic agents is contraindicated due to additive effects. Dapasmart is not recommended during pregnancy unless clearly needed and under strict medical supervision, and should be avoided during breastfeeding.
Possible side effect
Common side effects (occurring in >5% of patients) include dry mouth, blurred vision, dizziness, drowsiness, and mild constipation. Less frequent adverse reactions (1-5% incidence) may comprise nausea, vomiting, headache, nervousness, weakness, and insomnia. Infrequent but clinically significant side effects (<1%) include palpitations, tachycardia, urinary hesitation or retention, increased ocular tension, and allergic reactions ranging from skin rash to anaphylaxis. Paradoxical reactions such as restlessness and excitement may occur, particularly in elderly patients. Long-term use at high dosages has been associated with cognitive effects including memory impairment and confusion. Most side effects are dose-dependent and often diminish with continued therapy or dosage adjustment.
Drug interaction
Dapasmart exhibits significant interaction potential with several medication classes. Concurrent administration with other anticholinergic agents (including tricyclic antidepressants, phenothiazines, and antiparkinsonian drugs) may produce additive anticholinergic effects. CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) may increase dicyclomine plasma concentrations, while inducers (rifampin, carbamazepine) may reduce efficacy. Absorption of Dapasmart may be decreased when administered with antacids or antidiarrheal medications; separate administration by at least 2 hours. The medication may enhance sedative effects when combined with CNS depressants including alcohol, benzodiazepines, and opioids. Dapasmart may reduce gastrointestinal motility and affect absorption of other orally administered drugs, particularly those with narrow therapeutic indices.
Missed dose
If a dose of Dapasmart is missed, patients should take it as soon as remembered unless it is nearly time for the next scheduled dose. In such cases, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should never double the dose to make up for a missed administration, as this increases the risk of adverse effects. If multiple doses are missed or uncertainty exists regarding dosing schedule, patients should contact their healthcare provider for guidance. Consistent adherence to the prescribed regimen is important for maintaining therapeutic effect, particularly in chronic management. Patients may benefit from setting reminders or using pill organizers to minimize missed doses.
Overdose
Dapasmart overdose manifests primarily as anticholinergic crisis, characterized by severe dry mouth, blurred vision, hyperthermia, tachycardia, urinary retention, and CNS effects ranging from excitement to seizures. In severe cases, cardiovascular collapse, respiratory depression, and coma may occur. Management involves immediate gastric lavage or activated charcoal if ingestion was recent, followed by supportive care including temperature control, fluid administration, and monitoring of vital signs. Physostigmine may be considered in severe cases with life-threatening symptoms, but should be administered cautiously due to risk of cholinergic crisis. Symptomatic treatment for specific manifestations (benzodiazepines for seizures, cooling measures for hyperthermia) should be implemented as needed. Patients should be monitored for at least 24 hours due to the medication’s extended half-life.
Storage
Store Dapasmart tablets at controlled room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Protect from moisture and light by keeping tablets in their original blister packaging until administration. Do not store in bathrooms or other areas with high humidity. Keep out of reach of children and pets. Do not use tablets that show signs of damage to the enteric coating or discoloration. Properly dispose of expired or unused medication through medication take-back programs or according to local regulations. Do not flush medications down the toilet or drain unless specifically instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Dapasmart is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to therapy may vary, and not all patients will experience the described benefits. The prescribing physician should consider the complete medical history and current medication regimen of each patient before initiating treatment. Patients should report any adverse effects or concerns to their healthcare provider promptly. This information does not replace professional medical judgment and should not be used as the sole basis for treatment decisions.
Reviews
Clinical studies demonstrate that 78% of patients experienced significant reduction in abdominal pain within two weeks of Dapasmart initiation. Gastroenterologists report high satisfaction with its predictable efficacy and manageable side effect profile compared to older antispasmodic agents. Patient surveys indicate improved quality of life scores, with particular emphasis on reduced disruption of daily activities and social functioning. Long-term follow-up studies (12-24 months) show maintained efficacy without development of tolerance in most patients. Some clinicians note that the enteric coating significantly improves gastrointestinal tolerability compared to non-coated formulations. Critical analysis suggests Dapasmart performs particularly well in patients with diarrhea-predominant IBS, though it remains effective across IBS subtypes when spasmodic pain is a primary concern.